Bilirubin may limit heart ischemia and reperfusion injury in diabetic rats

Bilirubin may limit heart ischemia and reperfusion injury in diabetic rats

International Journal of Cardiology 214 (2016) 390 Contents lists available at ScienceDirect International Journal of Cardiology journal homepage: w...

141KB Sizes 0 Downloads 47 Views

International Journal of Cardiology 214 (2016) 390

Contents lists available at ScienceDirect

International Journal of Cardiology journal homepage: www.elsevier.com/locate/ijcard

Correspondence

Bilirubin may limit heart ischemia and reperfusion injury in diabetic rats Yao Lu a,⁎, Jun Hu b, Xuesheng Liu a a b

Department of Anesthesiology, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province, PR China Department of Anesthesiology, Tongling People's Hospital, Tongling, Anhui Province, PR China

a r t i c l e

i n f o

Article history: Received 24 March 2016 Accepted 27 March 2016 Available online 6 April 2016 Keywords: Bilirubin Diabetes Myocardial ischemia-reperfusion Heme oxygenase-1

can confer cardioprotection against myocardial ischemia and reperfusion injury in diabetes rats via restoring HIF-1α/HO-1 signaling pathway. Thus, from these above studies, we speculate heme oxygenase-1 (HO-1) derived bilirubin may also produce cardioprotection against myocardial ischemia and reperfusion injury in diabetes rats as in non-diabetic rats. In summary, we do agree with the authors' conclusion that antioxidative damage contributes to the cardioprotection of bilirubin. However, the role of heme oxygenase-1 (HO-1) was not determined. Conflict of interest The authors have no conflict of interest to declare.

To the Editor We have greatly read the report of Bakrania et al. [1] “Pre- or postischemic bilirubin ditaurate treatment reduces oxidative tissue damage and improves cardiac function”, the authors showed that pre- and postischemic treatment with bilirubin ditaurate (BDT) significantly limit ischemia injury in isolated Langendorff perfused hearts. And, their study also indicated that post-treatment is particularly effective. Heme oxygenase-1 (HO-1) is the first and rate limiting enzyme in the heme breakdown to generate bilirubin, free ferrous iron and carbon monoxide [2]. Heme oxygenase-1 (HO-1) and its reaction products have been shown to have both anti-oxidant and anti-inflammatory properties, indicating a protective role of HO-1 in myocardial infarction [3]. Moreover, HO-1 may also contribute to why experimental diabetic models are more resistant to ischemic preconditioning induced cardioprotection, since HO-1 protein expression is reduced in diabetic rats [4]. HO-1 inhibition has been shown to exacerbate inflammatory response, thus inducing endothelial cell death in animal models of atherosclerosis [5]. It has been demonstrated that heme oxygenase-1 (HO-1) derived bilirubin can prevent endothelial cells against high glucose-induced damage [6]. Studies have also shown that increased expression of HO-1 attenuated glucosemediated cell growth arrest and apoptosis and decreased endothelial cell sloughing in diabetic rats [3,7]. Hypoxia inducible factor-1 (HIF-1α) is an upstream of HO-1. HIF-1α induced up-regulation of HO-1 can produce cardioprotective effects in non-diabetic rats [8]. Mao et al. [9] found that antioxidants N-acetylcysteine (NAC) and allopurinol (ALP) ⁎ Corresponding author at: Department of Anesthesiology, First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, PR China. E-mail address: [email protected] (Y. Lu).

http://dx.doi.org/10.1016/j.ijcard.2016.03.233 0167-5273/© 2016 Elsevier Ireland Ltd. All rights reserved.

Financial Support National Natural Science Foundation of China (No. 81100105). References [1] B. Bakrania, et al., Pre- or post-ischemic bilirubin ditaurate treatment reduces oxidative tissue damage and improves cardiac function, Int. J. Cardiol. 202 (2016) 27–33. [2] G.M. Trakshel, M.D. Maines, Multiplicity of heme oxygenase isozymes. HO-1 and HO2 are different molecular species in rat and rabbit, J. Biol. Chem. 264 (1989) 1323–1328. [3] S. Quan, P.M. Kaminski, L. Yang, et al., Heme oxygenase-1 prevents superoxide anion associated endothelial cell sloughing in diabetic rats, Biochem. Biophys. Res. Commun. 315 (2004) 509–516. [4] S. Turkseven, A. Krugger, C. Mingone, et al., Antioxidant mechanism of heme oxygenase-1 involves an increase in superoxide dismutase and catalase in experimental diabetes, Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H701–H707. [5] K. Ishikawa, M. Navab, N. Leitinger, et al., Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL, J. Clin. Invest. 100 (1997) 1209–1216. [6] M. He, M. Nitti, S. Pairas, et al., Heme oxygenase-1-derived bilirubin protects endothelial cells against high glucose-induced damage, Free Radic. Biol. Med. 89 (2015) 91–98. [7] N.G. Abraham, T. Kushida, J. McClung, et al., Heme oxygenase-1 attenuates glucosemediated cell growth arrest and apoptosis in human microvessel endothelial cells, Circ. Res. 93 (2003) 507–514. [8] R. Ockaili, R. Natarajan, F. Salloum, et al., HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation, Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H542–H548. [9] X. Mao, T. Wang, Y. Liu, et al., N-acetylcysteine and allopurinol confer synergy in attenuating myocardial ischemia injury via restoring HIF-1α/HO-1 signaling in diabetic rats, PLoS One 8 (2013), e68949.